RNXT · RenovoRx Inc
United States · RS rating 80 · As of 2026-11-03
| Price | 1.29 USD |
|---|---|
| 1-day change | +2.4% |
| RS rating (overall / 1M / 3M / 12M) | 80 / 32 / 90 / 65 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 43 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +33.3% |
| Sales growth Q/Q | -10.5% |
| Distance from 52-week high | +48.8% |
| Market cap (USD) | $40.5M |